# Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data

> **NCT05393245** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 19467 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium+Olodaterol
- **DEVICE:** Spiolto Respimat
- **DRUG:** Long-acting muscarinic antagonists (LAMAs)
- **DRUG:** Long-acting β2-agonists (LABAs)

## Key facts

- **NCT ID:** NCT05393245
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-30
- **Primary completion:** 2022-12-07
- **Final completion:** 2022-12-07
- **Target enrollment:** 19467 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05393245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05393245, "Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05393245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*